Ischemic heart disease (IHD) was the leading cause of deaths worldwide in 2010 and is currently the leading cause of deaths (12.4%) in India. Platelet inhibitors were shown to reduce the rate of thrombotic events in patients with acute coronary syndrome. However, these agents are associated with a risk of bleeding. Recently, research has focused on the efficacy and safety of intensifying antiplatelet therapy in atherosclerotic patients with an agent that can target a different pharmacologic pathway.
One of these pathways targets protease-activated receptor (PAR)-1 that facilitates thrombosis, through selective inhibition. Here, we discuss a drug molecule vorapaxar for reduction of thrombotic cardiovascular events in patients with a history of MI or with peripheral arterial disease (PAD). Vorapaxar sulfate, a protease-activated receptor-1 (PAR-1) antagonist. It is co-administrated with…
